Chimeric Therapeutics Management
Management criteria checks 1/4
Chimeric Therapeutics' CEO is Jennifer Chow, appointed in Aug 2021, has a tenure of 2.75 years. total yearly compensation is A$3.03M, comprised of 28% salary and 72% bonuses, including company stock and options. directly owns 2.12% of the company’s shares, worth A$488.55K. The average tenure of the management team and the board of directors is 2.5 years and 2.8 years respectively.
Key information
Jennifer Chow
Chief executive officer
AU$3.0m
Total compensation
| CEO salary percentage | 28.0% |
| CEO tenure | 2.8yrs |
| CEO ownership | 2.1% |
| Management average tenure | 2.5yrs |
| Board average tenure | 2.8yrs |
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -AU$12m |
| Sep 30 2023 | n/a | n/a | -AU$19m |
| Jun 30 2023 | AU$3m | AU$849k | -AU$26m |
| Mar 31 2023 | n/a | n/a | -AU$22m |
| Dec 31 2022 | n/a | n/a | -AU$18m |
| Sep 30 2022 | n/a | n/a | -AU$17m |
| Jun 30 2022 | AU$3m | AU$758k | -AU$16m |
| Mar 31 2022 | n/a | n/a | -AU$19m |
| Dec 31 2021 | n/a | n/a | -AU$21m |
| Sep 30 2021 | n/a | n/a | -AU$18m |
| Jun 30 2021 | AU$2m | AU$306k | -AU$15m |
Compensation vs Market: Jennifer's total compensation ($USD1.98M) is above average for companies of similar size in the Australian market ($USD292.20K).
Compensation vs Earnings: Jennifer's compensation has increased whilst the company is unprofitable.
CEO
Jennifer Chow
2.8yrs
Tenure
AU$3,033,010
Compensation
Ms. Jennifer Chow has been a Director of Chimeric Therapeutics Limited since August 30, 2021. She serves as the Managing Director & Chief Executive Officer of Chimeric Therapeutics Limited since August 30,...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Executive Chairman | 4.3yrs | AU$250.00k | 11.15% A$ 2.6m | |
| CEO, MD & Director | 2.8yrs | AU$3.03m | 2.12% A$ 488.6k | |
| Chief Business Officer & Head of External Innovation | 2.3yrs | AU$1.26m | 0% A$ 0 | |
| Chief Medical Officer | 1.8yrs | AU$1.13m | no data | |
| CFO, Joint Company Secretary & Director | 3.6yrs | no data | 1.21% A$ 278.8k | |
| VP & Head of Quality | 2.3yrs | no data | no data | |
| Company Secretary | 3.6yrs | no data | no data |
2.5yrs
Average Tenure
62yo
Average Age
Experienced Management: CHM's management team is considered experienced (2.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Executive Chairman | 4.3yrs | AU$250.00k | 11.15% A$ 2.6m | |
| CEO, MD & Director | 2.8yrs | AU$3.03m | 2.12% A$ 488.6k | |
| CFO, Joint Company Secretary & Director | less than a year | no data | 1.21% A$ 278.8k | |
| Member of Glioblastoma Expert Advisory Board | no data | no data | no data | |
| Non-Executive Director | 3.8yrs | AU$73.32k | 0.20% A$ 47.0k | |
| Member of Cellular Immunotherapy Scientific Advisory Board | 2.7yrs | no data | no data | |
| Member of Glioblastoma Expert Advisory Board | no data | no data | no data | |
| Member of Glioblastoma Expert Advisory Board | 3.3yrs | no data | no data | |
| Chairman of Glioblastoma Expert Advisory Board | no data | no data | 0% A$ 0 | |
| Member of Cellular Immunotherapy Scientific Advisory Board | 2.8yrs | no data | no data | |
| Member of Cellular Immunotherapy Scientific Advisory Board | 2.7yrs | no data | no data | |
| Member of Cellular Immunotherapy Scientific Advisory Board | 2.7yrs | no data | no data |
2.8yrs
Average Tenure
65yo
Average Age
Experienced Board: CHM's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.